Literature DB >> 19769915

Incongruous changes in heart period and heart rate variability with vagotonic atropine: implications for rehabilitation medicine.

Glen Picard1, Can Ozan Tan, Ross Zafonte, J Andrew Taylor.   

Abstract

OBJECTIVE: To describe the relationship between vagally mediated bradycardia and heart rate variability indices in young and older healthy individuals.
DESIGN: Cross-sectional, physiologic study.
SETTING: Outpatient cardiovascular research laboratory. PARTICIPANTS: A total of 34 young (mean age 24 years) and 27 older (mean age 63 years) healthy adults.
METHODS: Eight bolus injections of atropine sulfate were given intravenously to participants while in a supine position (cumulative doses from 0.4 to 7.2 microg/kg). Each dose was followed by a 3-minute data collection period in which subjects controlled their breathing frequency at a rate of 15 breaths per minute. MAIN OUTCOME MEASUREMENTS: Chronotropic responses were assessed from average RR interval and blood pressure was assessed by automated brachial cuff. Heart rate variability (HRV) indices were calculated to represent both time domain measures (RR interval standard deviation and root mean squared of successive differences) and frequency domain measures (respiratory sinus arrhythmia and total power).
RESULTS: RR interval responses exhibited the expected curvilinear pattern to atropine administration with all subjects exhibiting a bradycardia with at least one dose and RR interval returning to baseline or decreasing in most subjects as atropine dosing progressed. RR interval was closely related to vagotonic atropine dose with an r(2) greater than 0.70 in 89% of subjects. Heart rate variability indices were not consistently correlated with the bradycardic effect of vagotonic atropine and ranged from highly positive to highly negative with almost one-fifth of correlations less than 0.5.
CONCLUSIONS: The relationship between HRV and vagal tone is likely complex and has a large interindividual variation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19769915     DOI: 10.1016/j.pmrj.2009.07.017

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  8 in total

1.  Major depressive disorder with melancholia displays robust alterations in resting state heart rate and its variability: implications for future morbidity and mortality.

Authors:  Andrew H Kemp; Daniel S Quintana; Candice R Quinn; Patrick Hopkinson; Anthony W F Harris
Journal:  Front Psychol       Date:  2014-11-27

Review 2.  Everything Hertz: methodological issues in short-term frequency-domain HRV.

Authors:  James A J Heathers
Journal:  Front Physiol       Date:  2014-05-07       Impact factor: 4.566

3.  The effects of psychosocial stress on intergroup resource allocation.

Authors:  Adam Schweda; Nadira Sophie Faber; Molly J Crockett; Tobias Kalenscher
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

4.  Exhausted Heart Rate Responses to Repeated Psychological Stress in Women With Major Depressive Disorder.

Authors:  Carmen Schiweck; Ali Gholamrezaei; Maxim Hellyn; Thomas Vaessen; Elske Vrieze; Stephan Claes
Journal:  Front Psychiatry       Date:  2022-04-18       Impact factor: 5.435

5.  Heart rate variability: are there complex patterns?

Authors:  Can Ozan Tan
Journal:  Front Physiol       Date:  2013-07-04       Impact factor: 4.566

Review 6.  Considerations in the assessment of heart rate variability in biobehavioral research.

Authors:  Daniel S Quintana; James A J Heathers
Journal:  Front Psychol       Date:  2014-07-22

7.  Resistance Exercise Training on Disease Impact, Pain Catastrophizing and Autonomic Modulation in Women with Fibromyalgia.

Authors:  Alaina Glasgow; Tori M Stone; J Derek Kingsley
Journal:  Int J Exerc Sci       Date:  2017-12-01

Review 8.  Post-exercise Body Cooling: Skin Blood Flow, Venous Pooling, and Orthostatic Intolerance.

Authors:  Afton D Seeley; Gabrielle E W Giersch; Nisha Charkoudian
Journal:  Front Sports Act Living       Date:  2021-05-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.